{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:19:08Z","timestamp":1793755148470,"version":"4.6.1"},"reference-count":132,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":126,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.riam.2024.11.001","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T15:42:19Z","timestamp":1740757339000},"page":"68-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Antifungal pipeline: New tools for the treatment of mycoses"],"prefix":"10.1016","volume":"41","author":[{"given":"Stella","family":"Wolfgruber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Salmanton-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius Paulin Ngouanom","family":"Kuate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Guillermo Pereira","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2024.11.001_bib0665","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fcimb.2020.00469","article-title":"Immunomodulation for the treatment of fungal infections: opportunities and challenges","volume":"10","author":"Ademe","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.riam.2024.11.001_bib0670","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/abhs.abhs_35_22","article-title":"Antiparasitic properties of miltefosine-based nanoformulations against protozoan pathogen, Acanthamoeba castellanii","volume":"1","author":"Akbar","year":"2022","journal-title":"Adv Biomed Health Sci"},{"key":"10.1016\/j.riam.2024.11.001_bib0675","first-page":"106587","article-title":"Ibrexafungerp, a novel triterpenoid antifungal in development for the treatment of mold infections","volume":"8","author":"Angulo","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2024.11.001_bib0680","doi-asserted-by":"crossref","first-page":"100115","DOI":"10.1016\/j.simyco.2021.100115","article-title":"Aspergillus fumigatus and aspergillosis: from basics to clinics","volume":"100","author":"Arastehfar","year":"2021","journal-title":"Stud Mycol"},{"key":"10.1016\/j.riam.2024.11.001_bib0685","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/13543784.2020.1791820","article-title":"Oral ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis","volume":"29","author":"Azie","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.riam.2024.11.001_bib0690","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02343-20","article-title":"Manogepix, the active moiety of the investigational agent fosmanogepix, demonstrates in vitro activity against members of the Fusarium oxysporum and Fusarium solani species complexes","volume":"65","author":"Badali","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib0695","doi-asserted-by":"crossref","first-page":"106587","DOI":"10.1016\/j.ijantimicag.2022.106587","article-title":"Reducing the off-target endocrinologic adverse effects of azole antifungals-can it be done?","volume":"59","author":"Balcerek","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.riam.2024.11.001_bib0700","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/10600280221091301","article-title":"Ibrexafungerp in the treatment of vulvovaginal candidiasis","volume":"57","author":"Barnes","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.riam.2024.11.001_bib0705","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/myc.12869","article-title":"Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project","volume":"62","author":"Bassetti","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2024.11.001_bib0710","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3390\/molecules28020692","article-title":"Identifying potential molecular targets in fungi based on (dis)similarities in binding site architecture with proteins of the human pharmacolome","volume":"28","author":"Bedoya-Cardona","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.riam.2024.11.001_bib0715","doi-asserted-by":"crossref","first-page":"101438","DOI":"10.1016\/j.mycmed.2023.101438","article-title":"Fungal diseases in Africa: closing the gaps in diagnosis and treatment through implementation research and advocacy","volume":"33","author":"Bongomin","year":"2023","journal-title":"J Mycol Med"},{"key":"10.1016\/j.riam.2024.11.001_bib0720","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial","volume":"77","author":"Boulware","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib0725","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121312","article-title":"Advances in antifungal drug development: an up-to-date mini review","volume":"14","author":"Bouz","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.riam.2024.11.001_bib0730","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/jac\/dkx177","article-title":"In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates","volume":"72","author":"Buil","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.riam.2024.11.001_bib0735","article-title":"1157. Clinical safety, efficacy, and pharmacokinetics of fosmanogepix, a novel first-in-class antifungal, in patients with renal insufficiency: subset analysis from a phase 2 candidemia trial","volume":"7","author":"Bulpa","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib0740","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/myc.13510","article-title":"Current situation of endemic mycosis in the Americas and the Caribbean: proceedings of the first international meeting on endemic mycoses of the Americas (IMEMA)","volume":"65","author":"Caceres","year":"2022","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2024.11.001_bib0745","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/antibiotics12050884","article-title":"Antifungals: From pharmacokinetics to clinical practice","volume":"12","author":"Carmo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.riam.2024.11.001_bib0750","article-title":"Amphotericin B and other polyenes-discovery, clinical use, mode of action and drug resistance","volume":"6","author":"Carolus","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2024.11.001_bib0755","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00067-8","article-title":"Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap","author":"Daneshnia","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.riam.2024.11.001_bib0760","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: a novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med Mycol"},{"key":"10.1016\/j.riam.2024.11.001_bib0765","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1021\/acsbiomedchemau.2c00055","article-title":"Antifungal development and the urgency of minimizing the impact of fungal diseases on public health","volume":"3","author":"de Oliveira","year":"2023","journal-title":"ACS Bio Med Chem Au"},{"key":"10.1016\/j.riam.2024.11.001_bib0770","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.46.8.2704-2707.2002","article-title":"Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis","volume":"46","author":"Delmas","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib0775","article-title":"Global incidence and mortality of severe fungal disease","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib0780","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00807-19","article-title":"The siderophore transporter Sit1 determines susceptibility to the antifungal VL-2397","volume":"63","author":"Dietl","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib0785","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1016\/S2666-5247(21)00190-7","article-title":"The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey","volume":"3","author":"Driemeyer","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.riam.2024.11.001_bib0790","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00231-18","article-title":"Effect of the novel antifungal drug F901318 (olorofim) on growth and viability of Aspergillus fumigatus","volume":"62","author":"Du Pr\u00e9","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib0795","doi-asserted-by":"crossref","first-page":"e0234520","DOI":"10.1128\/AAC.02345-20","article-title":"Preliminary characterization of NP339, a novel polyarginine peptide with broad antifungal activity","volume":"65","author":"Duncan","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib0800","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s11046-023-00776-4","article-title":"Predictors for prolonged hospital stay solely to complete intravenous antifungal treatment in patients with candidemia: Results from the ECMM Candida III multinational European Observational Cohort Study","volume":"188","author":"Egger","year":"2023","journal-title":"Mycopathologia"},{"key":"10.1016\/j.riam.2024.11.001_bib0805","unstructured":"EMA. EMADOC-628903358-4019: European Medicines Agency; 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu3202385-public-summary-opinion-orphan-designation-rezafungin-acetate-treatment-invasive-candidiasis_en.pdf."},{"key":"10.1016\/j.riam.2024.11.001_bib0810","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/myc.12890","article-title":"Clinical mycology in Latin America and the Caribbean: a snapshot of diagnostic and therapeutic capabilities","volume":"62","author":"Falci","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2024.11.001_bib0815","unstructured":"(FDA) UFaDA. Highlights of prescribing information, IMPAVIDO (miltefosine) capsules, for oral use. 2014."},{"key":"10.1016\/j.riam.2024.11.001_bib0820","unstructured":"(FDA) UFaDA. BREXAFEMME\u00ae (ibrexafungerp tablets), for oral use. Product Insert. 2021. Available from: https:\/\/www.brexafemme.com\/sites\/default\/files\/2022-11\/prescribing-information.pdf."},{"key":"10.1016\/j.riam.2024.11.001_bib0825","unstructured":"(FDA) UFaDA. Highlights of prescribing information, VIVJOA (oteseconazole) capsules, for oral use 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215888s000lbl.pdf."},{"key":"10.1016\/j.riam.2024.11.001_bib0830","unstructured":"(FDA) UFaDA. Highlights of prescribing information, REZZAYO (rezafungin for injection), for intravenous use 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217417s000lbl.pdf."},{"key":"10.1016\/j.riam.2024.11.001_bib0835","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/jof8101077","article-title":"Antifungal Combinations against Candida species: from bench to bedside","volume":"8","author":"Fioriti","year":"2022","journal-title":"J Fungi"},{"key":"10.1016\/j.riam.2024.11.001_bib0840","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.riam.2024.11.001_bib0845","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/idoj.idoj_310_23","article-title":"Ibrexafungerp: a novel oral triterpenoid antifungal","volume":"15","author":"Francis","year":"2024","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.riam.2024.11.001_bib0850","unstructured":"GAFFI. Antifungal drug maps. Available from: https:\/\/drugsmaps.azurewebsites.net\/maps\/map\/."},{"key":"10.1016\/j.riam.2024.11.001_bib0855","doi-asserted-by":"crossref","first-page":"642358","DOI":"10.3389\/fcimb.2021.642358","article-title":"Ibrexafungerp, a novel oral triterpenoid antifungal in development: overview of antifungal activity against Candida glabrata","volume":"11","author":"Gamal","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.riam.2024.11.001_bib0860","article-title":"Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garcia-Effron","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2024.11.001_bib0865","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1128\/CMR.12.4.501","article-title":"Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"Ghannoum","year":"1999","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.riam.2024.11.001_bib0870","article-title":"605. Efficacy and pharmacokinetics\u2013pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis","volume":"9","author":"Giamberardino","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib0875","doi-asserted-by":"crossref","first-page":"e0147623","DOI":"10.1128\/jcm.01476-23","article-title":"Universal digital high-resolution melting for the detection of pulmonary mold infections","volume":"62","author":"Goshia","year":"2024","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.riam.2024.11.001_bib0880","doi-asserted-by":"crossref","first-page":"e0154023","DOI":"10.1128\/aac.01540-23","article-title":"Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis","volume":"68","author":"Gu","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib0885","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1021\/acs.cgd.2c00843","article-title":"Integral role of water in the solid-state behavior of the antileishmanial drug miltefosine","volume":"22","author":"Hall","year":"2022","journal-title":"Cryst Growth Des"},{"key":"10.1016\/j.riam.2024.11.001_bib0890","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/antibiotics12091413","article-title":"Antifungal use and resistance in a lower-middle-income country: the case of Lebanon","volume":"12","author":"Hassoun","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.riam.2024.11.001_bib0895","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1128\/AAC.00366-11","article-title":"Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis","volume":"55","author":"Hata","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib0900","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01623-22","article-title":"Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers","volume":"67","author":"Hodges","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib0905","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/jac\/dks155","article-title":"European Organization for the Research and Treatment of Cancer\/Mycoses Study Group (EORTC\/MSG) host factors and invasive fungal infections in patients with haematological malignancies","volume":"67","author":"Hoenigl","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib0910","doi-asserted-by":"crossref","DOI":"10.1111\/myc.12836","article-title":"Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: new leadership is about working together","author":"Hoenigl","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2024.11.001_bib0915","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib0920","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.riam.2024.11.001_bib0925","doi-asserted-by":"crossref","first-page":"ii21","DOI":"10.1093\/jac\/dkac353","article-title":"Liposomal amphotericin B-the future","volume":"77","author":"Hoenigl","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib0930","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/s41564-022-01172-2","article-title":"COVID-19-associated fungal infections","volume":"7","author":"Hoenigl","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.riam.2024.11.001_bib0935","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/13543784.2022.2086120","article-title":"Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action","volume":"31","author":"Hoenigl","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.riam.2024.11.001_bib0940","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s11046-023-00790-6","article-title":"Treatment of Fusarium infection of the central nervous system: a review of past cases to guide therapy for the ongoing 2023 outbreak in the United States and Mexico","volume":"188","author":"Hoenigl","year":"2023","journal-title":"Mycopathologia"},{"key":"10.1016\/j.riam.2024.11.001_bib0945","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00872-6","article-title":"Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study","author":"Hoenigl","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib0950","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00074-23","article-title":"Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease","author":"Hoenigl","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.riam.2024.11.001_bib0955","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11046-024-00852-3","article-title":"Exploring European consensus about the remaining treatment challenges and subsequent opportunities to improve the management of invasive fungal infection (IFI) in the intensive care unit","volume":"189","author":"Hoenigl","year":"2024","journal-title":"Mycopathologia"},{"key":"10.1016\/j.riam.2024.11.001_bib0960","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01157-17","article-title":"Pharmacodynamics of the orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease","volume":"8","author":"Hope","year":"2017","journal-title":"mBio"},{"issue":"Suppl. 2","key":"10.1016\/j.riam.2024.11.001_bib0965","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/mmy\/myy052","article-title":"Broad spectrum triazoles for invasive mould infections in adults: which drug and when?","volume":"57","author":"Jenks","year":"2019","journal-title":"Med Mycol"},{"key":"10.1016\/j.riam.2024.11.001_bib0970","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/myc.13067","article-title":"Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: analysis of patients in the FungiScope\u00ae Registry","volume":"63","author":"Jenks","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2024.11.001_bib0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2020.01.012","article-title":"Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope\u00ae registry 2008\u20132019","author":"Jenks","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2024.11.001_bib0980","doi-asserted-by":"crossref","DOI":"10.1111\/myc.13274","article-title":"Invasive aspergillosis in critically ill patients: review of definitions and diagnostic approaches","author":"Jenks","year":"2021","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2024.11.001_bib0985","doi-asserted-by":"crossref","first-page":"102325","DOI":"10.1016\/j.eclinm.2023.102325","article-title":"Social determinants of health as drivers of fungal disease","volume":"66","author":"Jenks","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.riam.2024.11.001_bib0990","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00833-17","article-title":"De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring echinocandin resistance","volume":"61","author":"Jim\u00e9nez-Ortigosa","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib0995","article-title":"An open-label study in healthy volunteers to evaluate the potential for cytochrome P450 3A4 inhibition by F901318 using oral midazolam as a probe","volume":"49","author":"Kennedy","year":"2017","journal-title":"Ratio"},{"key":"10.1016\/j.riam.2024.11.001_bib1000","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/jac\/dkw325","article-title":"Global access to antifungal therapy and its variable cost","volume":"71","author":"Kneale","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1005","article-title":"New treatment options for critically important WHO fungal priority pathogens","author":"Kriegl","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2024.11.001_bib1010","doi-asserted-by":"crossref","first-page":"ofae270","DOI":"10.1093\/ofid\/ofae270","article-title":"Antifungals in patients with extracorporeal membrane oxygenation: clinical implications","volume":"11","author":"Kriegl","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib1015","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2174\/1566524023666230302123310","article-title":"Molecular targeting and novel therapeutic approaches against fungal infections","volume":"23","author":"Kumar","year":"2023","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.riam.2024.11.001_bib1020","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1093\/jac\/dky329","article-title":"Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei","volume":"73","author":"Lackner","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/jdi.13183","article-title":"Opportunistic invasive fungal disease in patients with type 2 diabetes mellitus from Southern China: clinical features and associated factors","volume":"11","author":"Lao","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.riam.2024.11.001_bib1030","doi-asserted-by":"crossref","first-page":"e0158423","DOI":"10.1128\/aac.01584-23","article-title":"Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis","volume":"68","author":"Locke","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1035","doi-asserted-by":"crossref","first-page":"114775","DOI":"10.1016\/j.addr.2023.114775","article-title":"Fungal infections: immune defense, immunotherapies and vaccines","volume":"196","author":"Loh","year":"2023","journal-title":"Adv Drug Delivery Rev"},{"key":"10.1016\/j.riam.2024.11.001_bib1040","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00724-19","article-title":"Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis","volume":"10","author":"Lu","year":"2019","journal-title":"MBio"},{"key":"10.1016\/j.riam.2024.11.001_bib1045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40268-021-00376-x","article-title":"Pharmacokinetics and pharmacodynamics of ibrexafungerp","volume":"22","author":"McCarthy","year":"2022","journal-title":"Drugs R D"},{"key":"10.1016\/j.riam.2024.11.001_bib1050","doi-asserted-by":"crossref","first-page":"732223","DOI":"10.3389\/fcimb.2021.732223","article-title":"Antifungal pipeline","volume":"11","author":"McCarty","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.riam.2024.11.001_bib1055","unstructured":"Micoses MdSdBPdCd. Paracoccidioidomicose. Available from: www.gov.br\/saude\/pt-br\/assuntos\/saude-de-a-a-z\/p\/pcm."},{"key":"10.1016\/j.riam.2024.11.001_bib1060","doi-asserted-by":"crossref","first-page":"dlad141","DOI":"10.1093\/jacamr\/dlad141","article-title":"Antifungal resistance and stewardship: a knowledge, attitudes and practices survey among pharmacy students at the University of Zambia; findings and implications","volume":"5","author":"Mudenda","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.riam.2024.11.001_bib1065","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/jof6040373","article-title":"PC945, a Novel inhaled antifungal agent, for the treatment of respiratory fungal infections","volume":"6","author":"Murray","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2024.11.001_bib1070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ja.2016.107","article-title":"ASP2397: a novel antifungal agent produced by Acremonium persicinum MF-347833","volume":"70","author":"Nakamura","year":"2017","journal-title":"J Antibiot"},{"key":"10.1016\/j.riam.2024.11.001_bib1075","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/infdis\/jix479","article-title":"Pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus","volume":"217","author":"Negri","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib1080","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12889-021-10783-z","article-title":"Barriers and coping mechanisms to accessing healthcare during the COVID-19 lockdown: a cross-sectional survey among patients with chronic diseases in rural Rwanda","volume":"21","author":"Nshimyiryo","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.riam.2024.11.001_bib1085","doi-asserted-by":"crossref","first-page":"e0006046","DOI":"10.1371\/journal.pntd.0006046","article-title":"Histoplasmosis in Africa: an emerging or a neglected disease?","volume":"12","author":"Oladele","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib1090","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.riam.2024.11.001_bib1095","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical Evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1100","article-title":"Fungal drug response and antimicrobial resistance","volume":"9","author":"Osset-Tr\u00e9nor","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2024.11.001_bib1105","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cmi.2023.03.008","article-title":"COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases","volume":"29","author":"\u00d6zbek","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2024.11.001_bib1110","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.healun.2020.09.015","article-title":"Successful salvage therapy for fungal bronchial anastomotic infection after -lung transplantation with an inhaled triazole anti-fungal PC945","volume":"39","author":"Pagani","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.riam.2024.11.001_bib1115","doi-asserted-by":"crossref","first-page":"106459","DOI":"10.1016\/j.ijantimicag.2021.106459","article-title":"An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis","volume":"59","author":"Pali\u0107","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.riam.2024.11.001_bib1120","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib1125","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40265-022-01751-x","article-title":"Global consumption trend of antifungal agents in humans from 2008 to 2018: data from 65 middle- and high-income countries","volume":"82","author":"Pathadka","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.riam.2024.11.001_bib1130","doi-asserted-by":"crossref","first-page":"e0014223","DOI":"10.1128\/cmr.00142-23","article-title":"Advancements and challenges in antifungal therapeutic development","volume":"37","author":"Puumala","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.riam.2024.11.001_bib1135","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S1473-3099(17)30306-7","article-title":"Neglected endemic mycoses","volume":"17","author":"Queiroz-Telles","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib1140","series-title":"Hope on the horizon: novel fungal treatments in development. Open Forum Infectious Diseases","year":"2020"},{"key":"10.1016\/j.riam.2024.11.001_bib1145","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.3201\/eid2810.220391","article-title":"Demographic and socioeconomic factors associated with fungal infection risk, United States, 2019","volume":"28","author":"Rayens","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib1150","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1017\/ash.2023.471","article-title":"Antifungal stewardship: the Latin American experience","volume":"3","author":"Riera","year":"2023","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"10.1016\/j.riam.2024.11.001_bib1155","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jac\/dkz078","article-title":"In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1160","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.FUNK-0002-2016","article-title":"Antifungal drugs: the current armamentarium and development of new agents","volume":"4","author":"Robbins","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.riam.2024.11.001_bib1165","doi-asserted-by":"crossref","first-page":"106718","DOI":"10.1016\/j.ijantimicag.2023.106718","article-title":"The current state of laboratory mycology in Asia\/Pacific: a survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM)","volume":"61","author":"Salmanton-Garc\u00eda","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.riam.2024.11.001_bib1170","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S2666-5247(22)00261-0","article-title":"The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey","volume":"4","author":"Salmanton-Garc\u00eda","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.riam.2024.11.001_bib1175","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/myc.13650","article-title":"The Austrian landscape of diagnostic capacity and access to treatment for invasive fungal infections","volume":"66","author":"Salmanton-Garc\u00eda","year":"2023","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2024.11.001_bib1180","doi-asserted-by":"crossref","first-page":"ofz534","DOI":"10.1093\/ofid\/ofz534","article-title":"The diagnostic laboratory hub: a new health care system reveals the incidence and mortality of tuberculosis, histoplasmosis, and cryptococcosis of PWH in Guatemala","volume":"7","author":"Samayoa","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.riam.2024.11.001_bib1185","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1190","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01817-16","article-title":"Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1195","unstructured":"SCYNEXIS. SCYNEXIS announces positive results from interim analyses of ongoing phase 3 studies (FURI and CARES), demonstrating oral ibrexafungerp's ability to treat severe fungal infections in the hospital setting 2021. Available from: https:\/\/ir.scynexis.com\/news-events\/press-releases\/detail\/233\/scynexis-announces-positive-results-from-interim-analyses."},{"key":"10.1016\/j.riam.2024.11.001_bib1200","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2666-5247(24)00039-9","article-title":"Impact of climate change and natural disasters on fungal infections","volume":"5","author":"Seidel","year":"2024","journal-title":"The Lancet Microbe."},{"key":"10.1016\/j.riam.2024.11.001_bib1205","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00129-19","article-title":"Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease","volume":"63","author":"Seyedmousavi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1210","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/jof8090909","article-title":"GR-2397: review of the novel siderophore-like antifungal agent for the treatment of invasive aspergillosis","volume":"8","author":"Shaw","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2024.11.001_bib1215","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1128\/AAC.05954-11","article-title":"T-2307 causes collapse of mitochondrial membrane potential in yeast","volume":"56","author":"Shibata","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1220","doi-asserted-by":"crossref","first-page":"e20495","DOI":"10.1016\/j.heliyon.2023.e20495","article-title":"Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis (RVVC) \u2013 a systematic review and meta-analysis","volume":"9","author":"Siddiqui","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.riam.2024.11.001_bib1225","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2217\/fmb-2021-0173","article-title":"Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis","volume":"16","author":"Sobel","year":"2021","journal-title":"Future Microbiol"},{"key":"10.1016\/j.riam.2024.11.001_bib1230","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/1040841X.2015.1068271","article-title":"Caspofungin: pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes","volume":"42","author":"Song","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.riam.2024.11.001_bib1235","doi-asserted-by":"crossref","first-page":"e103113","DOI":"10.1371\/journal.pone.0103113","article-title":"Incidence of Cyp51 a key mutations in Aspergillus fumigatus \u2013 a study on primary clinical samples of immunocompromised patients in the period of 1995\u20132013","volume":"9","author":"Spiess","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.riam.2024.11.001_bib1240","doi-asserted-by":"crossref","DOI":"10.1016\/j.cub.2020.07.032","article-title":"Fungal pathogens","volume":"30","author":"Sun","year":"2020","journal-title":"Curr Biol"},{"key":"10.1016\/j.riam.2024.11.001_bib1245","unstructured":"TheWorldBank. The World by Income and Region, Current Classification by income 2024. Available from: https:\/\/datatopics.worldbank.org\/world-development-indicators\/the-world-by-income-and-region.html?_gl=1*1bjyvqh*_gcl_au*OTgxMjMyMjYwLjE3MjQzMjUyNTE."},{"key":"10.1016\/j.riam.2024.11.001_bib1250","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.riam.2024.11.001_bib1255","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.2147\/IDR.S274872","article-title":"Candidemia: evolution of drug resistance and novel therapeutic approaches","volume":"14","author":"Tortorano","year":"2021","journal-title":"Infect Drug Resist"},{"issue":"Suppl. 3","key":"10.1016\/j.riam.2024.11.001_bib1260","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1093\/mmy\/myz012","article-title":"Antifungal drugs: what brings the future?","volume":"57","author":"Van Daele","year":"2019","journal-title":"Med Mycol"},{"key":"10.1016\/j.riam.2024.11.001_bib1265","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/jof9020171","article-title":"Sources of antifungal drugs","volume":"9","author":"Vanreppelen","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2024.11.001_bib1270","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01419-22","article-title":"Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by Candida auris: results from a phase 2 trial","volume":"67","author":"Vazquez","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1275","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s15010-023-02084-x","article-title":"Laboratory and clinical management capacity for invasive fungal infections: the Italian landscape","volume":"52","author":"Vena","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.riam.2024.11.001_bib1280","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1285","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1290","unstructured":"WHO. WHO fungal priority pathogens list to guide research, development and public health action 2022. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240060241."},{"key":"10.1016\/j.riam.2024.11.001_bib1295","unstructured":"WHO. The selection and use of essential medicines: World Health Organization; 2023 [23rd list]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/371090\/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1."},{"key":"10.1016\/j.riam.2024.11.001_bib1300","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/jof7020130","article-title":"Review of T-2307, an investigational agent that causes collapse of fungal mitochondrial membrane potential","volume":"7","author":"Wiederhold","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2024.11.001_bib1305","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/TP.0000000000000153","article-title":"Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis in solid organ transplant patients: a semiprospective multicenter study","volume":"98","author":"Willinger","year":"2014","journal-title":"Transplantation."},{"key":"10.1016\/j.riam.2024.11.001_bib1310","doi-asserted-by":"crossref","first-page":"106819","DOI":"10.1016\/j.ijantimicag.2023.106819","article-title":"Miltefosine exhibits fungicidal activity through oxidative stress generation and Aif1 activation in Candida albicans","volume":"62","author":"Wu","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.riam.2024.11.001_bib1315","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00374-19","article-title":"The novel arylamidine t-2307 selectively disrupts yeast mitochondrial function by inhibiting respiratory chain complexes","volume":"63","author":"Yamashita","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2024.11.001_bib1320","doi-asserted-by":"crossref","first-page":"911322","DOI":"10.3389\/fmicb.2022.911322","article-title":"novel promising antifungal target proteins for conquering invasive fungal infections","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Microbiol"}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140625000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140625000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:26:17Z","timestamp":1772882777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140625000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":132,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1130140625000026"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2024.11.001","relation":{},"ISSN":["1130-1406"],"issn-type":[{"value":"1130-1406","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifungal pipeline: New tools for the treatment of mycoses","name":"articletitle","label":"Article Title"},{"value":"Revista Iberoamericana de Micolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.riam.2024.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Asociaci\u00f3n Espa\u00f1ola de Micolog\u00eda.","name":"copyright","label":"Copyright"}]}}